More Articles Back to Article
EMA to accelerate review of AZ, Daiichi Sankyo HER2 drug Enhertu
The European Medicines Agency will fast-track its review of AstraZeneca and Daiichi Sankyo's HER2-positive breast cancer candidate Enhertu, or trastuzumab deruxtecan. The FDA approved the antibody drug conjugate as a treatment for metastatic HER2-positive disease in December. PMLive (UK) (7/7)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!